GlaxoSmithKline Pharmaceuticals has informed that it enclosed a copy of Postal Ballot Notice pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which is being sent to the Members of the Company, seeking their approval for re-appointment of Juby Chandy as a Whole-time Director & Chief Financial Officer & Appointment of Somasundaram Palamadairamaswamy & Anup Wadhawan as an Independent Directors. In compliance with the Circulars of the Ministry of Corporate Affairs, the said Notice is being sent electronically only to those Members, whose names appear in the Register of Members/ List of Beneficial Owners as received from National Securities Depository (‘NSDL’)/ Central Depository Services (India) (‘CDSL’) and who have registered their e-mail addresses in respect of electronic holdings with NSDL/CDSL through the concerned Depository Participants and in respect of physical holdings with the Company’s Registrar and Share Transfer Agent (RTA) i.e. KFin Technologies (‘KFintech’) as on Friday, 21st March, 2025 (cut-off date). The e-voting shall commence on Monday, 31st March, 2025 at 09.00 am (IIST) till Tuesday, 29th April 2025 at 5.00 PM (IST). The copy of the said Notice is also available on the website of the Company at https://india-pharma.gsk.com/en-in/investors/shareholder-information/postal-ballot/ and on the website of Kfintech https://evoting.kfintech.com/.
The above information is a part of company’s filings submitted to BSE.